Moghadam Mehdi F, Tandon C, Aggarwal S, Singla S K, Singh S K, Sharma S K, Varshney G C, Jethi R K
Department of Biochemistry, Panjab University, Chandigarh-160014, India.
J Cell Biochem. 2003 Dec 15;90(6):1261-75. doi: 10.1002/jcb.10671.
Standardized calcium oxalate monohydrate (COM) crystal growth assay system was employed to study the ability of various test samples to influence growth rates of COM crystals. The inhibitory activity (IA) of various samples was expressed in terms of inhibitory units. Urine samples obtained from normal persons and kidney stone patients were found to have IA of 3.18 +/- 0.62 and 1.02 +/- 0.08, respectively. A potent inhibitor having molecular weight between 14.2 and 16.2 kDa was found to be primarily responsible for the differences observed in the urinary IAs between normal persons and kidney stone patients. The potent inhibitor was found to be tightly associated with a chromophore resembling Urobilirubin. An ELISA based assay system, using monoclonal antibodies against the above most potent inhibitor confirmed the difference observed in the urinary IA between the normal persons and kidney stone patients. This assay system has the potential to be routinely used to screen human beings for potential stone formers.
采用标准化的一水合草酸钙(COM)晶体生长测定系统,研究各种测试样品影响COM晶体生长速率的能力。各种样品的抑制活性(IA)以抑制单位表示。从正常人和肾结石患者获得的尿液样品的IA分别为3.18±0.62和1.02±0.08。发现一种分子量在14.2至16.2 kDa之间的强效抑制剂是造成正常人和肾结石患者尿液IA差异的主要原因。发现该强效抑制剂与一种类似尿胆红素的发色团紧密相关。一种基于ELISA的测定系统,使用针对上述最有效抑制剂的单克隆抗体,证实了正常人和肾结石患者尿液IA的差异。该测定系统有可能常规用于筛查有潜在结石形成风险的人群。